Pharmaceutical forecasting that survives contact with actuals
Portfolio demand forecasts built from molecule-level data, biosimilar uptake curves and UK market dynamics — refreshed automatically every month and scored against what actually happened. Not another spreadsheet that only one person understands.
Most pharmaceutical forecasts fail the same way: a revenue line extrapolated in Excel, assumptions buried in formulas, and no systematic check against what the market actually did. The forecast gets built once a year, argued over once a quarter, and quietly ignored the rest of the time.
Pharmaceutical forecasting done properly works the other way round. Demand is modelled in therapy units at molecule level, market growth and share are separated, biosimilar erosion and tender outcomes are explicit assumptions — and every month the model is rerun against fresh IQVIA and sales actuals, ideally fed straight from a governed pharmaceutical data warehouse, with variance reported automatically.
It is one of the most valuable places to apply AI in the pharmaceutical industry: the inputs are data-heavy, the logic is repeatable — exactly the conditions where AI forecasting models earn their keep — and the cost of a bad number, to supply, finance and credibility, is high.
What a pharma forecast has to get right
Pharmaceutical demand doesn't behave like consumer demand — the model has to reflect how the market actually works.
Portfolio, not one brand
A real pharma forecast covers every molecule and pack in the portfolio in one consistent model — not a different workbook, owner and logic per brand.
Biosimilar & LoE dynamics
Loss of exclusivity rewrites a molecule's economics in months. Uptake S-curves, switching speed and price erosion have to be explicit assumptions, not afterthoughts.
Market growth vs share
Volume moves for two different reasons — the market growing and your share changing. A forecast that blends them can't explain itself when the number misses.
NHS market structure
UK demand is shaped by commissioning policy, regional tenders and formulary decisions. Forecasts that ignore how the NHS actually buys drift fast.
Price & tender dynamics
Winning or losing a tender steps volume overnight; list-versus-net price gaps distort value forecasts. Both need to live in the model as first-class inputs.
Forecast vs actuals
Every monthly run is compared against what actually happened — variance surfaced, bias measured, assumptions corrected. That discipline is what makes the number credible.
Pharmaceutical AI forecasting models, without the black box
AI earns its place in a pharma forecast by doing the heavy, repeatable work — fitting uptake curves, learning seasonality, flagging drift — while every assumption stays visible and editable. This is how we build the models.
Patient-based vs trend-based models
Patient-based models build demand up from eligible patients, treatment rates and duration of therapy — essential for launches and loss-of-exclusivity events, where there is no history to extrapolate. Trend-based models project established brands from their own volume series. A credible portfolio forecast uses both and reconciles them.
Biosimilar erosion curves
Originator erosion and biosimilar share transfer are fitted as explicit S-curves, anchored to comparable UK launches and stepped for known tender dates — so the model shows when volume moves and why, rather than assuming a smooth decline.
Grounded in NHS & market data
Models are built on the data the UK market actually produces: IQVIA feeds, internal sales, and open NHS sources such as the Secondary Care Medicines Dataset (SCMD) for hospital use and the English Prescribing Dataset (EPD) for primary care — harmonised into consistent therapy units.
Self-correcting by design
Every run is scored against the next month's actuals. Variance and bias are reported automatically, drift is flagged early, and assumptions are updated — the model earns trust by showing its own track record, with your team's judgement staying in charge.
You can see this approach running in our interactive demos, or read how it has been applied for real portfolios in our case studies.
What a forecasting platform is worth
Supply, finance and commercial planning against the same forecast, built from the same assumptions — not three competing spreadsheets.
New actuals land, the model reruns, the outputs update. No two-week manual rebuild before anyone can look at the numbers.
When a market, brand or account moves off plan, it shows up in the next cycle — while there is still time to respond in-year.
Forecasting built for pharma, owned by you
Demand first, value second
We model therapy-unit demand at molecule level, then layer share, pack mix and price — so every driver of the number stays visible and challengeable.
Assumptions you control
Uptake curves, growth caps, tender outcomes and pricing sit in governed, editable inputs — the team owns the assumptions, the platform does the arithmetic.
Actuals wired in
IQVIA and internal sales feeds are integrated so every forecast is scored against reality each month, with variance and bias reported automatically.
Owned by you
You keep the model, the code and the data. No black-box licence — a forecasting platform your analysts can open, understand and extend.
Start with one portfolio
Bring us the portfolio your team struggles to forecast today. We'll build the demand model, wire in the actuals and hand over a platform that reruns itself every month — see how we did it in our automated forecasting case study, or explore our wider AI & data consulting services.
Common questions
Pharmaceutical forecasting is the process of projecting demand, volume and revenue for a pharmaceutical portfolio — by molecule, brand and market — so supply, finance and commercial teams are planning against the same number. A good forecast starts from patient-level or therapy-unit demand, layers on market share and uptake assumptions, and converts to packs and value, rather than extrapolating last year's sales line.
Part of our guide to AI in the pharmaceutical industry. See also pharma commercial analytics.